The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis
Authors:
- Kazunori NakamuraKNKazunori Nakamura
- Yukio FujitaYFYukio Fujita
- Hao ChenHCHao Chen
- Kohei SomekawaKSKohei Somekawa
- Fumihiro KashizakiFKFumihiro Kashizaki
- Harumi KoizumiHKHarumi Koizumi
- Kenichi TakahashiKTKenichi Takahashi
- Nobuyuki HoritaNobuyuki Horita
- Yu HaraYHYu Hara
- Shigeo MuroSMShigeo Muro
- Takeshi KanekoTKTakeshi Kaneko
Open Access
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a prevalent condition with fewer treatments available as the severity increases. Previous systematic reviews have demonstrated the benefits of long-term macrolide use. However, the therapeutic differences between different macrolides and the optimal duration of use remain unclear. Methods: A systematic review and meta-analysis were conducted to assess the effectiveness of long-term macrolide use in reducing COPD exacerbations, compare the therapeutic differences among macrolides, and determine the appropriate treatment duration. Four databases (PubMed, Cochrane Library, Web of Science, and ICHU-SHI) were searched until 20 March 2023, and a random-effects model was used to calculate the pooled effect. Results: The meta-analysis included nine randomized controlled trials involving 1965 patients. The analysis revealed an odds ratio (OR) of 0.34 (95% confidence interval [CI] 0.19, 0.59, p < 0.001) for the reduction in exacerbation frequency. Notably, only azithromycin or erythromycin showed suppression of COPD exacerbations. The ORs for reducing exacerbation frequency per year and preventing hospitalizations were −0.50 (95% CI: −0.81, −0.19; p = 0.001) and 0.60 (95% CI: 0.3, 0.97; p = 0.04), respectively. Statistical analyses showed no significant differences between three- and six-month macrolide prescriptions. However, studies involving a twelve-month prescription showed an OR of 0.27 (95% CI: 0.11, 0.68; p = 0.005; I2 = 81%). Although a significant improvement in St George’s Respiratory Questionnaire (SGRQ) total scores was observed with a mean difference of −4.42 (95% CI: −9.0, 0.16; p = 0.06; I2 = 94%), the minimal clinically important difference was not reached. While no adverse effects were observed between the two groups, several studies have reported an increase in bacterial resistance. Conclusions: Long-term use of azithromycin or erythromycin suppresses COPD exacerbations, and previous studies have supported the advantages of a 12-month macrolide prescription over a placebo.Keywords
This publication has 54 references indexed in Scilit:
- COPD and disease-specific health status in a working populationRespiratory Research, 2013
- Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trialRespiratory Research, 2013
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary DiseaseRespiration, 2010
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Exacerbations of chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 2007
- Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study GroupEuropean Respiratory Journal, 1994
- A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory QuestionnaireAmerican Review of Respiratory Disease, 1992
- The St George's Respiratory QuestionnaireRespiratory Medicine, 1991